Portage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Buys 7,000 Shares

Portage Biotech Inc. (NASDAQ:ALP – Get Free Report) insider Fiorenzo Villani bought 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were acquired at an average price of $5.07 per share, with a total value of $35,490.00. Following the completion of the transaction, the insider directly owned 22,219 shares of the company’s stock, valued at $112,650.33. This trade represents a 46.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Portage Biotech Stock Up 3.0%

ALP opened at $4.16 on Tuesday. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 1-year low of $3.20 and a 1-year high of $690.00. The company has a market capitalization of $6.45 million, a PE ratio of -0.51 and a beta of 0.54. The firm’s 50 day simple moving average is $10.53 and its two-hundred day simple moving average is $14.74.

Get Portage Biotech alerts:

Portage Biotech (NASDAQ:ALP – Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million for the quarter. As a group, equities analysts forecast that Portage Biotech Inc. will post -14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright started coverage on Portage Biotech in a report on Monday, August 17th. They set a “neutral” rating and a $12.50 price target for the company. Wall Street Zen raised Portage Biotech to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Finally, Zacks Research upgraded shares of Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $12.50.

View Our Latest Report on Portage Biotech

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.

See Also

• Five stocks we like better than Portage Biotech
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.